Rybelsus for weight loss and insulin resistance: what TikTok gets wrong

What did @arlethfranko actually say?

Honestly? It's hard to tell. The transcript from this 165K-view video is almost entirely incoherent. Phrases like "I have to think that the energy that we have to do is to have to have to look at the energy that we have" and references to "the President" and interview tables have nothing to do with Rybelsus, semaglutide, or insulin resistance.

The hashtags promise a personal GLP-1 experience story: #rybelsus, #semaglutide, #resistenciaainsulina (insulin resistance in Spanish), #ozempic, #tirzepatide. The caption says "Mi experiencia con Rybelsus" (My experience with Rybelsus). But the actual spoken content does not deliver that. Either this is a severely garbled auto-transcription of a Spanish-language video, or the content is simply off-topic. We cannot extract any specific medical claims from what was captured here.

One line does gesture toward a positive personal experience: "I think we have to be a one-person who I felt very well." That appears to be a fragment referencing feeling good, possibly on the medication. That's the closest thing to a factual claim in this transcript.

Does the science back this up?

We can't fact-check what wasn't coherently said. But we can address what the hashtags imply, because 165K people watched this, and many of them are probably curious about Rybelsus specifically.

Rybelsus (oral semaglutide) is the only GLP-1 receptor agonist approved by the FDA as a once-daily pill for type 2 diabetes. It is not approved for weight loss, unlike injectable semaglutide sold as Wegovy. The PIONEER trial program, which included PIONEER 1 through 10, established its efficacy for glycemic control. PIONEER 6 (Husain et al., 2019, New England Journal of Medicine) showed cardiovascular safety non-inferiority versus placebo in adults with type 2 diabetes at high cardiovascular risk.

For insulin resistance specifically, GLP-1 receptor agonists do improve insulin sensitivity, but the mechanism is largely indirect, working through weight loss and reduced glucotoxicity rather than directly repairing insulin signaling pathways. Claiming Rybelsus "fixes" insulin resistance would be an oversimplification the data does not support.

What did they get wrong (or right)?

We can't fairly accuse @arlethfranko of getting specific facts wrong because no specific facts were legibly stated. That's actually its own problem. A video with 165K views, hashtagged with five drug names, is implicitly offering medical guidance to a large audience. The community watching those hashtags is actively researching GLP-1 medications, often for self-treatment decisions.

What we can flag is what the hashtag framing gets wrong by implication. Grouping #ozempic and #tirzepatide alongside #rybelsus suggests these are interchangeable options. They are not. Ozempic is injectable semaglutide approved for type 2 diabetes. Wegovy is injectable semaglutide approved for chronic weight management. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist with a different mechanism and a distinct approval profile. Lumping them together misleads viewers about which drug is appropriate for which indication.

If the creator genuinely felt well on Rybelsus, that is consistent with patient-reported outcomes in the PIONEER studies, where tolerability was generally acceptable. That part, if it was said, is plausible.

What should you actually know?

If you found this video while researching Rybelsus, here is what the actual evidence says. Rybelsus (oral semaglutide 3mg, 7mg, 14mg) is taken once daily at least 30 minutes before food or other medications, with no more than 4 ounces of plain water. That timing requirement is strict because oral bioavailability of semaglutide is low, around 1%, and food significantly reduces absorption further. Davies et al. (2019, Lancet) reported HbA1c reductions of 0.9 to 1.4 percentage points across doses in adults with type 2 diabetes.

Side effects are real and common. Nausea affects roughly 15 to 20 percent of users in clinical trials, particularly at initiation. Gastrointestinal symptoms are the primary reason people discontinue. These are not minor inconveniences for everyone.

Rybelsus is not a weight loss drug in its approved form. If you are seeking GLP-1 therapy primarily for weight management and do not have type 2 diabetes, this is not the indicated product. Talk to a licensed prescriber about what is actually appropriate for your situation.

Bottom line on this video

The transcript is too garbled to fact-check in any meaningful way. The hashtag framing conflates several distinct medications and indications. The implied personal testimony, "I felt very well," is not a medical claim anyone should base decisions on. If you are 1 of the 165K who watched this looking for real information about oral semaglutide, the PIONEER trial series is publicly available and considerably more useful than what was captured here.